Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMK389 in Moderate to Severe Atopic Dermatitis
2020-003406-31Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing CMK389 with Placebo (2 arms). Primary endpoint: IGA response. Started Nov 2020; status: completed.
02
Drugs
CMK-389
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2020-003406-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003406-31.